Row 1: D Rose, J Xiang, S Wu, A Byars
Row 2: T deGrauw, M Korostenskaja, M Schapiro
Row 3: A Hershey, H Greiner, B Hallinan, T Glauser
Movement Disorders Clinics/Tourette Syndrome Clinics
he Movement Disorder studies patients with tics, Tourette syndrome, dystonia, chorea, tremor, ataxia, and psychogenic movement disorders as well as ADHD and Stroke. Ongoing research includes studies of the neurological basis for ADHD and Tourette symptoms using Transcranial Magnetic Stimulation (TMS), as well as treatment studies for Tourette Syndrome, ADHD, and Stroke.
Comprehensive Epilepsy Program
The Comprehensive Epilepsy Program includes New Onset Seizure Clinics and Intractable Epilepsy Clinics. A major focus of the clinical research activities is the investigation of the role of drug-gene interactions on the individual variation in anti-epileptic drug clinical response. Research is under way examining both the role that genetic variation in drug metabolizing enzymes, drug transporters and drug receptors play in clinical response and the impact of medication on gene expression and the resulting relationship between gene expression and drug response. A NIH UO1 grant is a 32-center trial based out of Cincinnati Children’s Hospital Medical Center and is the largest pediatric epilepsy trial ever funded in the United States continues to generate highly significant information on the management of children with epilepsy with recent highlights in medication adherence. The study is designed to better identify the pharmacokinetic, pharmacodynamic and pharmacogenetic factors that impact response to therapy.
Tuberous Sclerosis Program
This multispecialty program follows hundreds of patients with tuberous sclerosis but also patients with related disorders such as lymphangioleiomyomatosis (LAM). Through the pharmacological research efforts on everolimus and the understanding of the molecular nature of mTOR, research from the Tuberous Sclerosis Clinic lead to the FDA approval of everolimus for subependymal giant-cell astrocytomas and continues to build on the use of agents involved in mTor pathways for the treatment of neurological conditions.
Research in the Headache Center continues with emphasis on clinical trials and outcome studies. The blood genomic study on pediatric migraine is ongoing with publication of the effects of medication overuse and recent completion of studies on the menstrual effects of gene expression patterns in adolescents with menstrual-related migraine. Through combination with the MEG Center, a NIH sponsored study on the cortical effects of acute migraine has been developed with initial results demonstrating of cortical dysfunction toward complex task in children with migraine. In collaboration with the Division of Behavioral Medicine and Clinical Psychology, an NIH study investigation is near completion examining the role of coping skills training in the management of chronic migraine. Over the past year, a significant effort in collaboration with the Division of Behavioral Medicine and Clinical Psychology and Center for Clinical and Translation Research (Dr. Powers) and the Department of Biostatistics and Clinical Trials Statistical and Data Management Center at the University of Iowa has resulted in the development of a multi-site study investigating the comparative effectiveness of amitriptyline and topiramate in the prevention of pediatric migraine.
Comprehensive Neuromuscular Center
The Comprehensive Neuromuscular Center has developed an interdisciplinary research program that integrates clinical, translational and basic research strategies. Our specialists participate in clinical trials, working to identify improved therapies. In one such study, our neuromuscular team collaborates with specialists from Endocrine division. to study the effects of Insulin Growth Factor 1 (IGF-1) on the muscle function of boys with Duchenne Muscular Dystrophy.
Neurobehavioral Animal Core (Vorhees and Williams lab)
During the past year we reported data showing for the first time that the Neuropeptide S receptor (NPSR1) in brain is the sole receptor mediating the anxiety, activity, and stress modulating effects of Neuropeptide S, an endogenous peptide that modulates mood and represents a target for the development of new therapeutics that may help correct mood disorders.
The Magnetoencephalography (MEG) Center, created in 2006, noninvasively measures magnetic fields created by the brain’s electrical activity and provides high spatiotemporal information about functional brain activity. MEG is now used to map epileptogenic foci and eloquent brain function for pre-operative evaluation of epilepsy surgery, and hundreds of patients have benefited. Researchers at the MEG Center have developed 17 collaborative projects including the study of language function of the developing brain, identification of neuromagnetic abnormalities in migraine and localization of epileptic foci with high-frequency oscillations. Supported by a Trustee Grant and two National Institutes of Health grants, the research team has published about 26 MEG papers in peer-reviewed journals. Within five years, our program has become one of the leading clinical MEG sites in the world. We have trained 10 MEG scientists, six of whom have become department or lab directors at their hospitals or institutions.
The Comprehensive Neuromuscular Care Center has distinguished itself as a center of excellence for the management and care of our patients. The center provides comprehensive interdisciplinary care for optimal outcomes in patients from all over the United States and other countries with pediatric neuromuscular disorders, in particular Duchenne muscular dystrophy.
Besides the teaching and education of pediatric and neurology resident staff, the program has also been successful in the training of pediatric neuromuscular specialists who are now working at other pediatric institutions. The program is active in translational and clinical neuromuscular research. In particular, it brings together other specialties in collaborative research projects and clinical trials in Duchenne muscular dystrophy.